Eplerenone

Generic Name
Eplerenone
Brand Names
Inspra
Drug Type
Small Molecule
Chemical Formula
C24H30O6
CAS Number
107724-20-9
Unique Ingredient Identifier
6995V82D0B
Background

Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the ef...

Indication

For improvement of survival of stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and clinical evidence of congestive heart failure after an acute myocardial infarction.

Associated Conditions
Hypertension, LVEF <40% Congestive heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class II)
Associated Therapies
-
Clinical Trials
Related News

Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction

Phase 4
Completed
Conditions
Myocardial Infarction
Interventions
Drug: Eplerenone
Drug: Placebo
First Posted Date
2010-08-06
Last Posted Date
2020-12-22
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
1012
Registration Number
NCT01176968
Locations
🇸🇰

Univerzitna nemocnica Martin, Martin, Slovakia

🇸🇰

Vseobecna nemocnica Rimavska Sobota, Rimavska Sobota, Slovakia

🇸🇰

Kardiocentrum Nitra, s.r.o., Nitra, Slovakia

and more 71 locations

Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart Failure

Phase 3
Completed
Conditions
Heart Failure
Interventions
Drug: Placebo
Drug: Eplerenone
First Posted Date
2010-05-04
Last Posted Date
2020-12-22
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
221
Registration Number
NCT01115855
Locations
🇯🇵

Hakodate City Hospital, Hakodate, Hokkaido, Japan

🇯🇵

Hokkaido University Hospital, Sapporo, Hokkaido, Japan

🇯🇵

Hyogo Brain and Heart Center, Himeji, Hyogo, Japan

and more 51 locations

Aldosterone Blockade in Chronic Kidney Disease: Influence on Arterial Stiffness and Kidney Function

Phase 3
Terminated
Conditions
Chronic Kidney Disease
Interventions
Drug: Eplerenone
First Posted Date
2010-04-08
Last Posted Date
2012-02-08
Lead Sponsor
Lene Boesby
Target Recruit Count
54
Registration Number
NCT01100203
Locations
🇩🇰

Dept. Nephrology, Herlev Hospital, Herlev, Denmark

🇩🇰

Herlev Hospital, Herlev, Denmark

Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension

Not Applicable
Terminated
Conditions
Myocardial Remodeling
Interventions
Drug: Lactose Tablet
Drug: Eplerenone
First Posted Date
2009-09-18
Last Posted Date
2014-03-28
Lead Sponsor
Creighton University
Target Recruit Count
20
Registration Number
NCT00980031
Locations
🇺🇸

Creighton University Medical Center (including ambulatory centers), Omaha, Nebraska, United States

A Study of the Effects of Eplerenone and Amlodipine on Blood Pressure and Basal Metabolic Rate in Obese Hypertensives

First Posted Date
2009-01-19
Last Posted Date
2018-05-29
Lead Sponsor
University of Mississippi Medical Center
Target Recruit Count
10
Registration Number
NCT00825188
Locations
🇺🇸

The University of Mississippi Clinical Research Program, Jackson, Mississippi, United States

A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension

First Posted Date
2009-01-06
Last Posted Date
2021-06-02
Lead Sponsor
Novartis
Target Recruit Count
155
Registration Number
NCT00817635
Locations
🇺🇸

Horizon Research Group, Inc, Mobile, Alabama, United States

🇺🇸

Northwest Clinical Trials, Boise, Idaho, United States

🇺🇸

KRK Medical Research, Dallas, Texas, United States

and more 32 locations

A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension

First Posted Date
2008-09-25
Last Posted Date
2021-07-06
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
628
Registration Number
NCT00758524
Locations
🇺🇸

Novartis Pharmaceuticals, East Hanover, New Jersey, United States

Eplerenone in Systemic Right Ventricle

First Posted Date
2008-06-23
Last Posted Date
2017-03-22
Lead Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Target Recruit Count
26
Registration Number
NCT00703352
Locations
🇪🇸

Hospital Universitari de la Vall d'Hebron, Barcelona, Spain

A Study To Evaluate The Efficacy Of Eplerenone Compared With Losartan For The Treatment Of Patients With Mild To Moderate Hypertension

Phase 2
Terminated
Conditions
Hypertension
Interventions
Drug: Losartan
Drug: eplerenone
First Posted Date
2008-04-01
Last Posted Date
2009-12-01
Lead Sponsor
Pfizer
Target Recruit Count
248
Registration Number
NCT00649311
Locations
🇨🇳

Pfizer Investigational Site, Taipei, Taiwan

EPLERAF-Study: Eplerenone in the Prevention of Atrial Fibrillation Recurrences After Cardioversion

Phase 2
Terminated
Conditions
Atrial Fibrillation
Interventions
Drug: Placebo
Drug: Eplerenone
First Posted Date
2008-03-31
Last Posted Date
2012-02-10
Lead Sponsor
University Hospital, Saarland
Target Recruit Count
38
Registration Number
NCT00647192
Locations
🇩🇪

Universitätsklinikum des Saarlandes, Klinik für Innere Medizin III, Homburg/Saar, Germany

🇳🇱

Rijksuniversiteit Groningen, Universitair Medisch Centrum, Groningen, Netherlands

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy